ArticleJournal of ovarian research2025
Methylated ARHGAP40 DNA as a potential biomarker for early diagnosis in high-grade ovarian serous cancer.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ovarian cancer ranks as the eighth most common malignancy in women globally. Early detection remains a critical challenge for improving ovarian cancer diagnosis and treatment outcomes. Our prior study demonstrated that ARHGAP40 downregulation in basal cell carcinoma is attributed to CpG island hypermethylation. However, the expression and methylation status of ARHGAP40 in ovarian cancer remain unexplored. Here, we investigated ARHGAP40 protein expression in normal fallopian tubes, ovarian benign tumors, borderline tumors, low-grade serous carcinoma (LGSC) and high-grade serous carcinomas (HGSC). Methylation analysis of the ARHGAP40 was performed using bisulfite sequencing PCR (BSP). MethyLight assays were developed to detect methylated circulating tumor DNA (ctDNA) fragments of ARHGAP40. IHC results revealed absent or weak ARHGAP40 protein expression in 93.8% (30/32) of HGSC, 11.1% (2/18) of borderline tumors, and in 14.3% (1/7) of LGSC cases. ARHGAP40 protein expression was robust expressed in all normal fallopian tubes (15/15) and benign ovarian tumors (8/8). CpG island hypermethylation in the ARHGAP40 promoter showed a strong inverse correlation with protein expression (P < 0.001). Furthermore, methylated ctDNA for ARHGAP40 was detected in 80.0% (4/5) of HGSC patients' plasma, but not in benign tumor (0/3) and healthy controls (0/15). Our findings suggest that promoter hypermethylation may be a mechanism underlying ARHGAP40 silencing in HGSC. Detection of methylated ARHGAP40 ctDNA may serve as a noninvasive biomarker for early diagnosis and monitoring of HGSC. While our findings suggest the potential of methylated ARHGAP40 as an early diagnostic biomarker, the small sample size warrants validation in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.